- Joined
- Apr 9, 2026
- Messages
- 2,729
- Solutions
- 1
- Online time
- 13d 9h
- Reputation
- 8,586
introduction
This guide covers the dasatinib + quercetin (D+Q) height growth hypothesis. Including the biological rationale, how it might affect growth plates, and the evidence that’s currently available. Focusing on the role of cellular senescence in skeletal development.
what are dasatinib and quercetin?
Dasatinib is an anticancer drug, a second-generation tyrosine kinase inhibitor (TKI).
It potently inhibits BCR-ABL and SRC family kinases (non-receptor tyrosine kinases that interact to drive cell proliferation and survival)
Quercetin is a plant compound called a flavonoid. It inhibits phosphoinositide 3-kinase (PI3K) by antioxidant quercetin in ascite cells of Dalton’s lymphoma (DL) mice and down regulates the anti-poptoic proteins of Bcl-XL and Bcl-2
Senescence-Associated Secretory phenotype
Senescent cells accumulate in the body over time and release inflammatory molecules known as the senescence-associated secretory phenotype (SASP) that drive age-related diseases. Dasatinib and quercetin (D+Q) work together as senolytics because they target different survival pathways within these cells. Dasatinib promotes the death of senescent cells by inhibiting Src tyrosine kinase signaling, while quercetin targets anti-apoptotic
pathways such as BCL-xL. When chondrocytes become senescent, they begin producing SASP factors, including cytokines, chemokines, proteases, and growth factors. these molecules can induce a range of physiological responses in the surrounding microenvironment, including inflammation, growth arrest and tumorigenesis. Some early SASP factors, such as Transforming Growth Factor Beta (TGF-β), can even cause nearby healthy cells to become senescent, allowing senescence to spread. Stimulation with D+Q selectively eliminated senescent cells in both, cartilage explants and isolated human articular chondrocytes (HAC). While also increasing COL2A1, ACAN, and SOX9 expression.
results from studies
on rats, dasatinib inhibited chondrocyte proliferation which decreased growth plate thickness. This was a 4-12 weeks of usage proving that dasatinib has effects on the growth plates.This guide covers the dasatinib + quercetin (D+Q) height growth hypothesis. Including the biological rationale, how it might affect growth plates, and the evidence that’s currently available. Focusing on the role of cellular senescence in skeletal development.
what are dasatinib and quercetin?
Dasatinib is an anticancer drug, a second-generation tyrosine kinase inhibitor (TKI).
It potently inhibits BCR-ABL and SRC family kinases (non-receptor tyrosine kinases that interact to drive cell proliferation and survival)
Quercetin is a plant compound called a flavonoid. It inhibits phosphoinositide 3-kinase (PI3K) by antioxidant quercetin in ascite cells of Dalton’s lymphoma (DL) mice and down regulates the anti-poptoic proteins of Bcl-XL and Bcl-2
Senescence-Associated Secretory phenotype
Senescent cells accumulate in the body over time and release inflammatory molecules known as the senescence-associated secretory phenotype (SASP) that drive age-related diseases. Dasatinib and quercetin (D+Q) work together as senolytics because they target different survival pathways within these cells. Dasatinib promotes the death of senescent cells by inhibiting Src tyrosine kinase signaling, while quercetin targets anti-apoptotic
pathways such as BCL-xL. When chondrocytes become senescent, they begin producing SASP factors, including cytokines, chemokines, proteases, and growth factors. these molecules can induce a range of physiological responses in the surrounding microenvironment, including inflammation, growth arrest and tumorigenesis. Some early SASP factors, such as Transforming Growth Factor Beta (TGF-β), can even cause nearby healthy cells to become senescent, allowing senescence to spread. Stimulation with D+Q selectively eliminated senescent cells in both, cartilage explants and isolated human articular chondrocytes (HAC). While also increasing COL2A1, ACAN, and SOX9 expression.
results from studies
usage
if you plan on taking D+Q, i recommend using it for 2 days at the start of your cycle and drop it for 6 weeks, then u repeat the cycle again. you may face side effects like nausea and low energy.
if you plan on taking D+Q, i recommend using it for 2 days at the start of your cycle and drop it for 6 weeks, then u repeat the cycle again. you may face side effects like nausea and low energy.